3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Withdrawn
1
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Myeloid, Acute
117
Myelodysplastic Syndromes
73
Leukemia, Myelomonocytic, Chronic
34
Leukemia
30
Neoplasms
11
Carcinoma, Non-Small-Cell Lung
11
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Myeloproliferative Disorders
8
Lymphoma, Non-Hodgkin
8
Lymphoma
8
Leukemia, Myelomonocytic, Acute
8
Congenital Abnormalities
8
Recurrence
7
Multiple Myeloma
7
Lymphoma, Large B-Cell, Diffuse
6
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
6
Leukemia, Monocytic, Acute
6
Leukemia, Erythroblastic, Acute
6
Primary Myelofibrosis
5
Lung Neoplasms
5
Leukemia, Megakaryoblastic, Acute
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Hodgkin Disease
5
Hematologic Neoplasms
5
Anemia, Refractory, with Excess of Blasts
5
Prostatic Neoplasms
4
Myelodysplastic-Myeloproliferative Diseases
4
Melanoma
4
Lymphoma, Follicular
4
Pancreatic Neoplasms
3
Interventions
Fluorouracil
2
Docetaxel
2
thymoglobulin
1
temsirolimus
1
sargramostim
1
pirarubicin
1
pembrolizumab
1
pazopanib
1
fludarabine phosphate
1
fludarabine
1
cc-486
1
X-Rays
1
Whole-Body Irradiation
1
Trastuzumab
1
Tacrolimus
1
Surveys and Questionnaires
1
Rituximab
1
Radiotherapy
1
Proctectomy
1
Pemetrexed
1
Oxaliplatin
1
Mycophenolic Acid
1
Monatide (IMS 3015)
1
Metformin
1
Melphalan
1
Leucovorin
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Epirubicin
1
Drug Therapy
1
Diphenhydramine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Pathologic Complete Response
×
Azacitidine
×
Clear all
NCT01757535
2025-07-08
QUAZAR AML-001
Celgene
Phase 3
Completed
472 enrolled
24 charts
1 FDA